CD163 and astrocytoma (excluding glioblastoma): However, significantly more CD163‐positive GAMs were observed in IDH1R132H‐non‐mutant GBMs as compared to IDH1R132H‐non‐mutant astrocytomas of WHO grade II/III (Figure S3A–D).